|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.21 USD | +1.47% |
|
+2.18% | -8.96% |
| 11-25 | Health Care Up Amid Cyclical Bias -- Health Care Roundup | DJ |
| 11-22 | GC Biopharma USA Names Sean Zam as Head of Sales and Marketing | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last hours
Enjoy this offer
* See conditions on site
| Capitalization | 149B 141B 131B 117B 208B 12,562B 228B 1,622B 604B 5,153B 558B 546B 22,355B | P/E ratio 2024 * |
16.5x | P/E ratio 2025 * | 13.3x |
|---|---|---|---|---|---|
| Enterprise value | 207B 196B 182B 163B 290B 17,488B 318B 2,258B 841B 7,174B 777B 760B 31,120B | EV / Sales 2024 * |
3.29x | EV / Sales 2025 * | 3.17x |
| Free-Float |
59.04% | Yield 2024 * |
6.42% | Yield 2025 * | 6.56% |
More valuation ratios
* Estimated data
More news
Last Transcript: Pfizer, Inc.
More recommendations
More press releases
| 1 day | +1.47% | ||
| 1 week | +2.18% | ||
| 1 month | -7.39% | ||
| 3 months | -9.65% | ||
| 6 months | -8.55% | ||
| Current year | -8.96% |
1 week
25.61
26.45
1 month
24.4828.14
Current year
24.4831.54
1 year
24.4831.54
3 years
24.4861.71
5 years
24.4861.71
10 years
24.4861.71
| Director | Title | Age | Since |
|---|---|---|---|
Albert Bourla
CEO | Chief Executive Officer | 62 | 31/12/2018 |
David Denton
DFI | Director of Finance/CFO | 59 | 01/05/2022 |
Rady Johnson
CMP | Compliance Officer | 63 | 30/11/2013 |
| Manager | Title | Age | Since |
|---|---|---|---|
Suzanne Johnson
BRD | Director/Board Member | 66 | 31/08/2007 |
Helen Hobbs
BRD | Director/Board Member | 71 | 11/12/2011 |
Shantanu Narayen
BRD | Director/Board Member | 60 | 26/09/2013 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.74% | 380 M€ | +11.27% | - | |
| 9.37% | 20 M€ | +15.49% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +1.47% | +2.18% | -13.98% | -51.22% | 149B | ||
| +0.91% | +6.33% | +34.57% | +220.65% | 716B | ||
| +1.30% | +0.85% | +8.89% | +114.93% | 474B | ||
| -0.25% | -0.10% | +0.23% | -0.59% | 373B | ||
| -0.08% | +3.38% | +28.47% | +58.68% | 323B | ||
| -1.44% | +2.48% | -0.82% | +35.68% | 257B | ||
| +0.63% | +0.47% | +8.24% | -28.96% | 233B | ||
| -0.12% | -0.44% | +9.57% | +27.00% | 211B | ||
| +0.17% | +1.32% | +4.80% | +28.23% | 209B | ||
| +1.00% | -3.96% | +4.91% | +42.23% | 152B | ||
| Average | +0.36% | +1.38% | +8.49% | +44.66% | 309.77B | |
| Weighted average by Cap. | +0.42% | +2.21% | +13.45% | +78.81% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 62.91B 59.63B 55.47B 49.52B 88.14B 5,321B 96.6B 687B 256B 2,183B 236B 231B 9,468B | 63.25B 59.95B 55.77B 49.79B 88.62B 5,350B 97.12B 691B 257B 2,194B 238B 232B 9,520B |
| Net income | 8.78B 8.32B 7.74B 6.91B 12.3B 742B 13.48B 95.82B 35.68B 305B 32.97B 32.24B 1,321B | 11.23B 10.64B 9.9B 8.84B 15.73B 950B 17.24B 123B 45.65B 390B 42.18B 41.25B 1,690B |
| Net Debt | 58.24B 55.2B 51.36B 45.84B 81.6B 4,926B 89.43B 636B 237B 2,021B 219B 214B 8,766B | 52.13B 49.41B 45.97B 41.03B 73.03B 4,409B 80.04B 569B 212B 1,809B 196B 191B 7,845B |
More financial data
* Estimated data
Employees
88,000
Sector
Pharmaceuticals
Calendar
03/02/2025
- Q4 2024 Earnings Release (Projected)
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/11/24 | 26.21 $ | +1.47% | 22,023,022 |
| 27/11/24 | 25.83 $ | +0.23% | 28,242,085 |
| 26/11/24 | 25.77 $ | -1.53% | 33,001,020 |
| 25/11/24 | 26.17 $ | +2.03% | 57,707,647 |
| 22/11/24 | 25.65 $ | +2.07% | 41,896,988 |
Delayed Quote Nyse, November 29, 2024 at 06:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
26.21USD
Average target price
32.66USD
Spread / Average Target
+24.61%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PFE Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition